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Abstract 
Aortic stenosis (AS) is the most frequent heart valve disease. Surgical aortic valve 
replacement (SAVR) is the reference treatment. Transcatheter aortic valve implantation 
(TAVI) has emerged as an alternative treatment. New strategies for treating the AS are 
upcoming. The aim of the study was to assess if the clinical profile of octogenarian patients 
treated surgically before and after the TAVI program initiation has changed. We 
retrospectively included consecutive octogenarian patients, who underwent isolated SAVR, 
between January 2006 and December 2011 in a single high-volume center. We compared 
preoperative and postoperative characteristics before and after the initiation of TAVI 
(February 2009).  517 patients were included: 229 in the "before TAVI" group (2006-2008), 
288 in the "after TAVI" group (2009-2011). The mean age was 83.2±2.0 in the "before 
TAVI" group, 83.5 ± 2.1 in the "after TAVI" group (p=0.106). There were no significant 
differences in preoperative characteristics: NYHA class (p=0.374), history of heart failure 
(p=0.680), left ventricular ejection fraction (59.8±12.2% in the "before TAVI" group, 
59.9±11.3% in the "after TAVI" group, p=0.922), coronary artery disease (p=0.431), chronic 
pulmonary disease (p=0.363), previous cardiac surgery (p=0.085). The logistic EuroSCORE 
was 7.78±4.60% in the "before TAVI" group and 7.33±3.96% in the "after TAVI" group 
(p=0.236). The operative mortality (30-day) was comparable: 5.2% in the "before TAVI" 
group, 6.9% in the "after TAVI" group (p=0.424).  Thus, with the emergence of TAVI, the 
number of octogenarian patients operated on, their preoperative characteristics and the 
operative mortality remained comparable. 
Key words: aortic valve stenosis, aortic valve replacement, octogenarian, transcatheter aortic 
valve implantation 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
Introduction 
Aortic stenosis (AS) is the most frequently treated heart valve disease 
1
. The prevalence of AS 
increases with age and it affects around 10% of octogenarians 
2–6
. Surgical aortic valve 
replacement (SAVR) is the standard treatment with good long-term outcomes 
7–13
. An 
alternative treatment appeared in 2002 with the first transcatheter aortic valve implantation 
(TAVI) 
14
. TAVI is indicated in patients with severe and symptomatic AS who are not 
suitable for SAVR as assessed by a “heart team” 
15–17
, and should be considered in patients 
with high surgical risk who may still be suitable for surgery 
8,15,16
. Little is known about the 
impact of TAVI on the indications to SAVR in the elderly, and whether it has prompted an 
evolution in the characteristics of elderly patients who actually receive SAVR. In this study, 
we compared the preoperative features, peri-operative characteristics and 30-day 
postoperative outcomes of octogenarian patients who underwent isolated SAVR before and 
after the initiation of the TAVI program in a single tertiary center. 
Methods 
We analyzed data from consecutive patients aged over 80 years, who underwent 
isolated SAVR (i.e. without concomitant coronary artery bypass or other cardiac procedure), 
between January 1
st
, 2006 and December 31
st
, 2014. All patients were enrolled within a single 
tertiary center where the TAVI program started in February 2009. 
We distinguished 3 groups: the pre-TAVI group (patients operated between January 
1
st
, 2006 and December 31
st
, 2008), the post-TAVI 1 group (patients operated between 
January 1
st
, 2009 and December 31
st
, 2011) and the post-TAVI 2 group (patients operated 
between January 1
st
, 2012 and December 31
st
, 2014). 
Treatment strategies for individual patients were decided during weekly meetings of a 
multidisciplinary “heart valve team” including physicians (cardiologists, anesthesiologists, 
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geriatricians…) and surgeons working in the same heart valve clinic 
18
. The decision to 
perform SAVR or TAVI was based on the clinical evaluation by cardiologists, surgeons and 
geriatricians in charge of the patient and the Logistic EuroSCORE I in accordance with the 
national recommendations. These conform the latest European and American guidelines 
15,16
. 
The preoperative characteristics, peri-operative data and postoperative mortality and 
morbidity were collected prospectively at the time of hospital discharge and entered in a 
computerized database.  
 The following preoperative characteristics were compared between the pre-TAVI 
group and each post-TAVI group: mean age, proportion of very elderly patients (aged more 
than 85 years), gender, New York Heart Association (NYHA) class, history of acute heart 
failure, history of atrial fibrillation, history of prior pacemaker implantation and 
echocardiographic data (left ventricular ejection fraction, mean aortic valve gradient, aortic 
valve area). Data about baseline comorbidities were also analyzed including coronary artery 
disease (all patients had a coronary angiography before surgery), cerebrovascular disease, 
peripheral vascular disease, chronic renal failure (defined as a creatinine clearance <60 
mL/min according to the Cockcroft-Gault equation), chronic pulmonary disease (defined as 
abnormal pulmonary function tests or chronic use of bronchodilators or inhaled steroids), 
hypertension, diabetes mellitus, obesity (defined as a body mass index > 30 kg/m
2
). We used 
Logistic EuroSCORE I 
19
 to calculate the estimated operative risk of mortality.  
We assessed for the 3 groups the peri-operative data, including operative priority 
(salvage for surgery performed immediately, emergency for surgery within 24 hours, urgent 
for surgery within a few days and elective for planned surgery), the cardiopulmonary bypass 
and cross-clamp time, and the type of prosthesis used.  
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We compared the operative mortality (defined as death within 30 days of surgery) and 
the incidence of in-hospital postoperative complications (reoperation for bleeding, tamponade, 
prolonged ventilatory support, renal failure, stroke, blood transfusion, atrial fibrillation and 
pacemaker implantation) between the pre-TAVI and each post-TAVI group. 
 Continuous variables were expressed as mean ± standard deviation (SD) and were 
compared using the Student t-test. Normality of continuous variables was checked through the 
Kolmogorov-Smirnov test. Categorical variables were expressed as a percentage and were 
compared using either the ² test or the Fisher exact test. All reported p-values were 2-sided. 
A p-value < 0.05 was considered significant. Statistical analyses were performed using SAS 
version 9.3 (SAS Institute Inc). 
Results 
During the study period, 845 consecutive patients were included, 229 were in the pre-
TAVI group, 288 in the post-TAVI 1 group and 328 in the post-TAVI 2 group (figure 1). 
Over time, there was a trend towards an increase in the yearly rate of SAVR performed 
(figure 1). Similarly, there was an increase in the number of TAVI procedures among 
octogenarians, 72 cases between 2009 and 2011 and 202 cases between 2012 and 2014.   
Preoperative characteristics were comparable between the pre-TAVI group and the 
post-TAVI 1 group (table 1). Nonetheless, the post-TAVI 2 group was characterized by less 
females, lower prevalence of heart failure, of coronary artery disease, of severe left 
ventricular systolic dysfunction and greater prevalence of hypertension and obesity than the 
pre-TAVI group (table 1). Moreover, there was a trend towards less chronic pulmonary 
disease in the post-TAVI 2 group (table 1). The Logistic EuroSCORE I trended to decrease in 
the post-TAVI group 2 (table 1). The aortic valve area was larger in the 2 post-TAVI groups, 
compared with the pre-TAVI group (table 1). 
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Concerning peri-operative data, there were significantly more urgent surgeries and 
lower decrease of the cardiopulmonary bypass and cross-clamp time in the post-TAVI 1 
group (table 2). They were similar between the pre-TAVI group and the post-TAVI 2 group 
(table 2). The operative mortality was comparable (5.2% in the pre-TAVI group, 6.9% in the 
post-TAVI 1 group, 4.3% in the post-TAVI 2 group). Concerning the incidence of early 
postoperative complications, there were statistically more cases of renal failure in the post-
TAVI 1 group.  
Discussion  
This single center study conducted within a tertiary heart valve clinic showed that, 
despite the availability of TAVI, the total number of SAVR cases continued to increase. 
While there were no significant changes in preoperative characteristics during the first 3 years 
after the availability of TAVI, we observed a decrease in the Logistic EuroSCORE I over the 
following 3 years. Nonetheless, the statistical significance was not reached. By the way, the 
operative mortality of octogenarians who underwent SAVR remained globally stable over 
time. There were no relevant differences in terms of peri-operative data and incidence of 
postoperative complications.    
One previous single center study with similar design was performed in New Zealand 
20
, with a smaller number of patients (35 patients in the pre-TAVI group and 33 patients in the 
post-TAVI group). Opposed to our results, octogenarian patients undergoing SAVR in such 
study were older, had lower left ventricular ejection fraction and higher EuroSCORE II in the 
post-TAVI era. However, this investigation was significantly limited by a very little sample 
size and the absence of mortality cases in either group.  
We observed that the number of octogenarian patients undergoing surgery increased 
slightly in our institution over the study time frame, which is consistent with previous reports 
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10,21
. Several factors may explain this finding. First, the absolute number of patients with 
symptomatic severe AS continues to increase in an aging population. Second, the possibility 
of a less invasive treatment with TAVI leads to an increased number of patients referred to 
tertiary centers for investigations. A significant percentage of these patients (about 10%) will 
eventually benefit from SAVR after heart team discussion 
22
. Finally, recent large studies 
including SAVR patients with high operative-risk showed good results with an operative 
mortality of 6.5% in the PARTNER Trial 
8
,  4.5% in the CoreValve US Pivotal trial 
23
 and 
7.0% in an octogenarian high operative-risk Italian population 
24
. This supports an aggressive 
strategy in elderly patients.  
Concerning the preoperative risk profile, patients undergoing SAVR appeared to be 
less severe in more recent periods. This is confirmed by a slight decrease of the Logistic 
EuroSCORE I in the post-TAVI 2 group of our study. Such features have been described here 
for the first time. This is probably the expression of referral of higher-risk surgical cases. This 
reasonably leads to better case mix selection for SAVR and eventually reduction of observed 
operative mortality.  
In our study, the operative mortality was comparable, before TAVI 5.2% (2006-2008), 
after TAVI 6.9% (2009-2011) and 4.3% (2012-2014). A slight difference was observed for 
the post-TAVI 1 group and could be explained by significantly higher proportion of urgent 
surgeries. These operative mortality rates are consistent with those of recent studies which 
range from 3.4% to 7.0% 
8–10,13,21,23–26
. Nevertheless, specific data about isolated SAVR in 
patients aged more than 80 years are scarce. Most studies are heterogeneous and extracted 
from databases not dedicated to precisely describe this population.     
This retrospective analysis reported prospectively gathered information from a single 
tertiary-care referral center experience. It is thus limited in size, concerned a selected 
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population and may not be generalizable. Nevertheless, it remains to the best of our 
knowledge the largest study on this subject to date. Retrospective observational studies like 
ours are inherently vulnerable to selection bias and unidentified confounding. However, all 
the data were collected prospectively and there was no missing data at the exclusion of the 
own limitations of the database. 
Disclosure of interest 
The authors have no conflicts of interest to disclose.  
Sources of Funding: None 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 

!"#$%&'()*+,-'+.
/!& -0  +0  1'. , -2 3 3 4+42' +' $ 42+ #2 ''
.2++245*67'-'62++	8895:

2. Eveborn GW, Schirmer H, Heggelund G, Lunde P, Rasmussen K. The evolving epidemiology of 
valvular aortic stenosis. the Tromsø study. Heart Br Card Soc 2013;99:396–400. 
3. Lindroos M, Kupari M, Heikkilä J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: 
an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220–1225. 
4. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of 
valvular heart diseases: a population-based study. Lancet 2006;368:1005–1011. 
5. Otto CM, Prendergast B. Aortic-valve stenosis--from patients at risk to severe valve obstruction. N 
Engl J Med 2014;371:744–756. 
6. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. 
Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll 
Cardiol 1997;29:630–634. 
7. Carabello BA, Paulus WJ. Aortic stenosis. Lancet 2009;373:956–966. 
8. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, 
Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, 
Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ, PARTNER 
Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl 
J Med 2011;364:2187–2198. 
9. Langanay T, Flécher E, Fouquet O, Ruggieri VG, La Tour B De, Félix C, Lelong B, Verhoye J-P, 
Corbineau H, Leguerrier A. Aortic valve replacement in the elderly: the real life. Ann Thorac Surg
2012;93:70–77. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 8
10. Barreto-Filho JA, Wang Y, Dodson JA, Desai MM, Sugeng L, Geirsson A, Krumholz HM. Trends 
in aortic valve replacement for elderly patients in the United States, 1999-2011. JAMA
2013;310:2078–2085. 
11. Martínez-Sellés M, Gómez Doblas JJ, Carro Hevia A, García de la Villa B, Ferreira-González I, 
Alonso Tello A, Andión Ogando R, Ripoll Vera T, Arribas Jiménez A, Carrillo P, Rodríguez Pascual 
C, Casares i Romeva M, Borras X, Cornide L, López-Palop R, PEGASO Registry Group. Prospective 
registry of symptomatic severe aortic stenosis in octogenarians: a need for intervention. J Intern Med
2014;275:608–620. 
12. Walther T, Blumenstein J, Linden A van, Kempfert J. Contemporary management of aortic 
stenosis: surgical aortic valve replacement remains the gold standard. Heart Br Card Soc 2012;98 
Suppl 4:iv23–29. 
13. Vasques F, Messori A, Lucenteforte E, Biancari F. Immediate and late outcome of patients aged 
80 years and older undergoing isolated aortic valve replacement: a systematic review and meta-
analysis of 48 studies. Am Heart J 2012;163:477–485. 
14. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, 
Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific 
aortic stenosis: first human case description. Circulation 2002;106:3006–3008. 
15. Joint Task Force on the Management of Valvular Heart Disease of the European Society of 
Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri 
O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, Bonis M 
De, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers H-J, Schuler G, 
Stepinska J, Swedberg K, Takkenberg J, Oppell UO Von, Windecker S, Zamorano JL, Zembala M. 
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451–
2496. 
16. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, O’Gara PT, Ruiz CE, 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
Skubas NJ, Sorajja P, Sundt TM, Thomas JD, ACC/AHA Task Force Members. 2014 AHA/ACC 
Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report 
of the American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. Circulation 2014;129:2440–2492. 
17. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, 
Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, 
Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S, PARTNER Trial Investigators. 
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N 
Engl J Med 2010;363:1597–1607. 
18. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, Donal E, Prendergast B, Magne 
J, Canna G La, Piérard LA, Maurer G. ESC Working Group on Valvular Heart Disease position paper-
-heart valve clinics: organization, structure, and experiences. Eur Heart J 2013;34:1597–1606. 
19. Roques F, Michel P, Goldstone AR, Nashef SAM. The logistic EuroSCORE. Eur Heart J
2003;24:881–882. 
20. Wang TKM, Sathananthan J, Ramanathan T, Webster M, Ruygrok P. Isolated aortic valve 
replacement in octogenarians before and after the introduction of trans-catheter aortic valve 
implantation. Heart Lung Circ 2014;23:249–255. 
21. Brown JM, O’Brien SM, Wu C, Sikora JAH, Griffith BP, Gammie JS. Isolated aortic valve 
replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, 
and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg
2009;137:82–90. 
22. Auffret V, Boulmier D, Oger E, Bedossa M, Donal E, Laurent M, Sost G, Beneux X, Harmouche 
M, Verhoye J-P, Le Breton H. Predictors of 6-month poor clinical outcomes after transcatheter aortic 
valve implantation. Arch Cardiovasc Dis 2014;107:10–20. 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
23. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder 
M, Hermiller J, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, 
Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK, U.S. 
CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding 
prosthesis. N Engl J Med 2014;370:1790–1798. 
24. Eusanio M Di, Fortuna D, Palma R De, Dell’Amore A, Lamarra M, Contini GA, Gherli T, 
Gabbieri D, Ghidoni I, Cristell D, Zussa C, Pigini F, Pugliese P, Pacini D, Bartolomeo R Di. Aortic 
valve replacement: Results and predictors of mortality from a contemporary series of 2256 patients. J 
Thorac Cardiovasc Surg 2011;141:940–947. 
25. Eusanio M Di, Fortuna D, Cristell D, Pugliese P, Nicolini F, Pacini D, Gabbieri D, Lamarra M, 
RERIC (Emilia Romagna Cardiac Surgery Registry) Investigators. Contemporary outcomes of 
conventional aortic valve replacement in 638 octogenarians: insights from an Italian Regional Cardiac 
Surgery Registry (RERIC). Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg
2012;41:1247–1252. 
26. Saxena A, Poh C-L, Dinh DT, Reid CM, Smith JA, Shardey GC, Newcomb AE. Early and late 
outcomes after isolated aortic valve replacement in octogenarians: an Australasian Society of Cardiac 
and Thoracic Surgeons Cardiac Surgery Database Study. Eur J Cardio-Thorac Surg Off J Eur Assoc 
Cardio-Thorac Surg 2012;41:63–68.

M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
Figure legends
Figure 1. Number of octogenarian patients undergoing surgical aortic valve remplacement.    
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Table 1. Preoperative characteristics 
Variables Pre-TAVI              
(n = 229) 
Post-TAVI 1           
(n = 288) 
p Value
* Post-TAVI 2  
(n = 328) 
p Value
†
Age (years) 83.2 ± 2.0 83.5 ± 2.1 0.11 83.5 ± 2.1 0.09 
Age  85 years 49 (21%) 76 (26%) 0.19 92 (28%) 0.08 
Female 123 (54%) 152 (53%) 0.83 149 (45%) 0.05 
NYHA class 0.37  0.37
          I or II 133 (58%) 156 (54%)  203 (62%)  
          III or IV 96 (42%) 132 (46%)  125 (38%)  
Logistic EuroSCORE I 
(%) 
12.4 ± 5.9 
(10.4%) 
12.7 ± 6.2 
(10.7%) 
0.68 11.6 ± 5.1 
(10.1%) 
0.06
History of congestive heart 
failure 
56 (25%) 75 (26%) 0.68 37 (11%) < 0.001 
Atrial fibrillation 34 (15%) 58 (20%) 0.15 59 (18%) 0.35 
Permanent pacemaker 16 (7%) 13 (5%) 0.22 17 (5%) 0.37 
Coronary artery disease 51 (22%) 56 (19%) 0.43 33 (10%) < 0.001 
Cerebrovascular disease 12 (5%) 15 (5%) 0.99 16 (5%) 0.85 
Peripheral vascular disease 49 (21%) 67 (23%) 0.61 60 (18%) 0.36 
Chronic renal failure 11 (5%) 20 (7%) 0.31 24 (7%) 0.23 
Chronic pulmonary 
disease 
28 (12%) 28 (10%) 0.36 25 (8%) 0.07 
Previous cardiac surgery 7 (3%) 2 (1%) 0.08 6 (2%) 0.35 
Hypertension 135 (59%) 189 (66%) 0.12 227 (69%) 0.01 
Diabetes mellitus 19 (8%) 20 (7%) 0.56 27 (8%) 0.98 
Obesity
‡
40 (18%) 70 (24%) 0.06 80 (24%) 0.05 
LVEF (%)  60 ± 12 60 ± 11 0.92 61 ± 10 0.32 
LVEF < 50% 36 (17%) 43 (16%) 0.81 33 (10%) 0.02 
Mean aortic valve gradient 
(mmHg) 
51 ± 15 51 ± 17 0.70 52 ± 15 0.40 
Aortic valve area (cm²) 0.6 ± 0.1 0.7 ± 0.2 0.007 0.7 ± 0.2 < 0.001 
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; TAVI = 
transcatheter aortic valve implantation 
*
 p Value between pre-TAVI and post-TAVI 1 
†
 p Value between pre-TAVI and post-TAVI 2  
‡
 Obesity defined as a body mass index > 30 kg/m
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Table 2. Peri-operative data 
Variables Pre-TAVI              
(n = 229) 
Post-TAVI 1          
(n = 288) 
p Value* Post-TAVI 2 
(n = 328) 
p Value
†
Operation status  0.03  0.32
           Elective 227 (99%) 277 (96%)  321 (98%)  
           Urgent 2 (1%) 11 (4%)  7 (2%)  
Cardiopulmonary 
bypass time (min) 
57 ± 19 54 ± 14 0.01 57 ± 19 0.98 
Cross-clamp time 
(min) 
44 ± 15 42 ± 11 0.02 45 ± 16 0.45 
Bioprosthetic valves 229 (100%) 288 (100%) 1.00 328 (100%) 1.00 
TAVI = transcatheter aortic valve implantation 
*
 p Value between pre-TAVI and post-TAVI 1 
†
 p Value between pre-TAVI and post-TAVI 2  
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Table 3. Operative mortality and postoperative complications 
Variables Pre-TAVI              
(n = 229) 
Post-TAVI 1           
(n = 288) 
p Value* Post-TAVI 2 
(n = 328) 
p Value
†
Operative mortality 
(30-day) 
15 (5.2%) 20 (6.9%) 0.42 14 (4.3%) 0.59 
Reoperation for 
bleeding 
5 (2%) 6 (2%) 1.00 10 (3%) 0.53 
Tamponade 7 (3%) 9 (3%) 0.96 16 (5%) 0.29 
Ventilatory support      
> 48h 
7 (3%) 16 (6%) 0.17 8 (2%) 0.66 
Renal failure 13 (6%) 36 (13%) 0.01 19 (6%) 0.95 
Stroke 2 (1%) 5 (2%) 0.47 1 (1%) 0.57 
Blood transfusion 97 (42%) 94 (32%) 0.94 104 (32%) 0.79 
Atrial fibrillation 112 (51%) 136 (48%) 0.54 163 (50%) 0.86 
Pacemaker implantation 5 (2%) 12 (4%) 0.21 5 (2%) 0.75 
TAVI = transcatheter aortic valve implantation 
*
 p Value between pre-TAVI and post-TAVI 1 
†
 p Value between pre-TAVI and post-TAVI 2  
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